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Abstract 
 
Neuropilins (NRPs) are co-receptors for class 3 semaphorins, and for members of the Vascular 
Endothelial Growth Factor (VEGF) family of angiogenic cytokines. Genetic analysis of the role 
of NRPs in mice shows that NRP1 is essential for embryonic neuronal path-finding and 
cardiovascular development, mediated via semaphorins and VEGF respectively, while NRP2 
has a more restricted role in neuronal patterning and lymphangiogenesis. NRPs are thought to 
mediate functional responses, most importantly cell migration, as a result of complex formation 
with other receptors, such as plexins in the case of semaphorins and the VEGF receptor, 
VEGFR2, resulting in enhanced signalling via some intracellular pathways. Recent findings 
indicate that NRPs may have important biological roles in other physiological and disease-
related processes. In particular, NRPs are highly expressed in diverse tumour cell lines and 
human neoplasms and have been implicated in several biological processes regulating tumour 
growth in vivo, suggesting that NRP1 may be a future therapeutic target in cancer.  
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Introduction 
 
Neuropilin-1 (NRP1) was discovered as the antigen recognised by the A5 monoclonal 
antibody, which localised in the tadpoles of Xenopus laevis to the neuropile, a superficial layer 
comprising a dense network of glial cells, synapses, axons, dendrites and neurons [1-3]. The 
subsequent generation of NRP1 mutants in mice and zebrafish established an essential role of 
this molecule in embryonic development of the vertebrate nervous and cardiovascular systems 
[4-7]. A key feature of NRP1 and the structurally related molecule, NRP2, is that they function 
as receptors for two unrelated types of secreted polypeptide ligand: class 3 semaphorins, a 
family of molecules with key roles in axonal guidance, and several members of the Vascular 
Endothelial Growth Factor (VEGF) family of angiogenic cytokines. In both cases NRP1 is 
important for regulating cell migration, but causes chemorepulsion in response to semaphorins, 
and chemotaxis in response to VEGF-A. However, despite the wealth of data regarding the 
developmental functions of NRPs, the cellular functions of NRPs are not entirely clear, and 
much uncertainty remains regarding the mechanisms through which NRPs mediate the 
biological effects of their ligands. Moreover, recent findings in diverse physiological and 
pathophysiological settings have greatly expanded the repertoire of biological processes in 
which NRPs potentially play an important role [8-10]. This chapter will review NRP biology 
with a focus on recent advances in understanding the role of NRPs in angiogenesis, in cell 
signalling and in disease. 
Neuropilin Structure 
 
NRP1 and NRP2 are transmembrane glycoproteins of up to 923 and 926 amino acids, respectively, 
sharing a similar domain structure and an overall amino acid homology of 44% [10,11]. NRPs comprise 
large extracellular regions containing two CUB (a1/a2) domains, sharing homology with the 
complement binding factors C1s/C1r, sea urchin fibropellins (called Uegf) and Bone Morphogenetic 
Protein 1 (BMP1), tandem Factor V/VIII homology (b1/b2) domains with homology to the C-terminal 
(C1/C2) domains of blood coagulation factors V and VIII [2], and a MAM (c) domain, a 170 amino acid 
region, also found in the extracellular domains of functionally diverse proteins, including meprin (a cell 
surface glycoprotein), A5 antigen, and receptor tyrosine protein phosphatase µ (MAM). NRPs have a 
single transmembrane domain and small cytoplasmic domains of 44 amino acids in NRP1 and 43 in 
NRP2 (Fig. 1). The carboxy-terminal three amino acids, SEA, present in NRP1 and the NRP2a isoform, 
form a consensus PDZ domain binding motif, which mediates association with a PDZ domain protein 
called neuropilin interacting protein-1 (NIP1), synectin or RGS-GAIP-interacting protein (GIPC) [12]. 
An important role of the extracellular region is ligand binding. The a1/a2 domains are essential 
for binding of semaphorins, while the b1 domain is required for VEGF-A165 binding with the 
b2 domain also necessary for optimal VEGF-A165 binding, and the b1/b2 domains are also 
important for semaphorin binding. The crystal structure of the NRP1 b1 domain displays a 
similarity to the three-dimensional structure of the FV/VIII C2 domain [13]. Crystal structures 
of the NRP1 b1 domain bound either to the peptide ligand, Tuftsin [14], to antibodies directed 
against either the VEGF or Sema3A binding domains [15], or to small molecule ligand 
mimetics [16], have identified the VEGF binding pocket and the key residues required for 
VEGF binding. The c or MAM domain has homology to other MAM domains present in 
diverse proteins, that are thought to mediate homophilic protein-protein associations important 
for homodimerisation or oligomerisation, and have also been implicated in regulating protein 
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stability. The MAM domain is thought to play a role in NRP-1 oligomerisation [17,18], though 
the function of this region of NRP1 is still poorly understood. 
NRP1 is a glycoprotein though the degree of glycosylation appears to vary between different 
cell types. In several tumour cell lines and in cultured vascular smooth muscle cells (VSMC) 
NRP1 also occurs as a high molecular weight glycosylated species of >250 kDa in addition to 
the major species of ~130 kDa corresponding to the full-length protein , and this modified form 
appears to be expressed at a lower level in cultured endothelial cells [19-21]. NRP1 is modified 
by addition of an O-linked heparan sulphate and/or chondroitin sulphate glycosaminoglycan 
(GAG) moiety preferentially to serine 612 in the linker region between the b2 and MAM 
domains (Fig. 1). In contrast, there is no evidence for a high molecular weight GAG modified 
form of NRP2. NRP1 and NRP2 are also modified by asparagine(N)-linked glycosylation as 
indicated by the effect of tunicamycin inhibition of N-glycosylation [22]. CS-GAG 
modification is reported to enhance both VEGF binding to neuropilin and cell survival, and to 
down-regulate VEGFR2 expression levels in vascular smooth muscle cells [19]. Further studies 
are needed to fully determine how glycosylation alters the ligand binding and other functional 
properties of NRPs. 
Neuropilin Ligands 
 
NRPs have the ability to bind with high affinity two structurally unrelated classes of 
ligands with distinct biological functions, the class 3 semaphorins and several members of the 
VEGF family. These ligand interactions are summarised in Fig. 2. 
 
Semaphorins 
 
The class 3 semaphorins are secreted proteins with essential roles in the axonal guidance and 
homing of sensory neurons, most of which require NRP1 or 2 as obligate co-receptors [23-25]. 
The major semaphorin ligand for NRP1 is Sema3A (also termed collapsin-1), which induces 
growth cone collapse in subsets of sensory and sympathetic neurons, including the dorsal root 
ganglia (DRG), and is essential for neurogenesis [26]. NRP1 also binds other secreted class 3 
semaphorins with lower affinity, though the biological roles of these interactions are less clear 
[10]. The best characterized semaphorin ligand for NRP2 is Sema 3F, and Semas 3B, 3C and 
3G, but not Sema3A, also bind NRP2 [10].  
VEGFs 
 
Vascular endothelial growth factor (VEGF or VEGF-A), also referred to in earlier literature as 
vascular permeability factor (VPF), is essential for both early formation of primordial blood 
vessels and endothelial cell differentiation from haematopoietic precursor cells 
(vasculogenesis) and for the sprouting of new vessels from pre-existing ones (angiogenesis) 
during development and in the adult [27]. In mammals, the VEGF family includes 5 members 
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encoded by different genes: VEGFs-A, -B, -C, -D and placental growth factor (PlGF). In 
addition, VEGF-E is encoded by the orf virus, and VEGF-F is found in snake venom [28-31]. 
Alternative splicing generates multiple VEGF-A isoforms with distinct but partly overlapping 
receptor affinities and specificities. VEGF-A occurs in at least six different isoforms: VEGF121, 
VEGF145, VEGF165, VEGF165b, VEGF189 and VEGF206 [31,32]. VEGF121 lacks exons 6 (coding 
for a sequence rich in basic amino acids involved in heparin binding) and 7, and has therefore 
been thought unable to bind either NRPs or heparin [33]. The most studied and what is 
generally thought to be the most active and abundant isoform, VEGF165, contains exon 7 but 
lacks exon 6, and is able to bind to both NRPs 1 and 2 [34]. VEGF145 lacks exon 7 and binds 
only to NRP2 [35]. The NRP1 b1 domain is essential for VEGF165 binding, and the b2 domain 
is additionally required for optimal binding, while the a1/a2 domains are largely dispensible for 
VEGF-A binding [36]. VEGF165 binds to NRPs with high affinity through its carboxy-terminal 
domain encoded by exons 7 and 8. A bicyclic peptide corresponding to the C-terminal 28 
amino acid residues of VEGF-A165 encoded by the C-terminal portion of exon 7 and all of exon 
8 selectively inhibits VEGF binding to NRP1 [37], and a peptide corresponding to exon 8 of 
VEGF-A165 and a naturally-occurring peptide with homology to exon 8, Tuftsin, also bind to 
NRP1 [14,38]. Antibodies specifically blocking VEGF165 binding to NRP1 also inhibited 
endothelial cell migration induced by VEGF121 [39]. VEGF121, lacking exon 7 but containing 
exon 8, binds NRP1 in vitro in surface plasmon resonance assays, but is unable to promote 
complex formation between NRP1 and VEGFR2 [39]. These findings are consistent with a 
model in which initial VEGF contacts with NRP1 are mediated via an interaction between the 
extreme carboxy-terminal residues encoded by exon 8 and the b1 domain (Fig. 3); binding and 
NRP1/VEGFR2 complex formation is either stabilised by further interactions between NRP1 
and exon 7-encoded residues and/or the exon 7 domain functions as a bridge between NRP1 
and VEGFR2. The larger isoforms, VEGF189 and VEGF206, bind heparin, are not readily 
diffusible, and are thought to remain sequestered by the extracellular matrix, but theoretically 
are able to bind NRP1. A novel isoform, VEGF-A165b, has been reported, with a distinct 
carboxy-terminus, RSLTRKD, encoded by an alternative exon 8 and is unable to stimulate 
endothelial cell proliferation, angiogenesis or other biological activities [40]. Possibly, the 
weaker biological activity of VEGF-A165b is due to its inability to bind NRP1 and thereby 
promote productive signalling complexes with VEGFR2 [37]. Other factors also influence 
VEGF binding to NRP1. The affinity of VEGF binding to NRP1, at least in vitro, is enhanced 
by heparin, and by increasing the density of NRP1 [41]. As mentioned above, CS-GAG 
modification of NRP1 also enhances VEGF binding [19]. 
VEGF-B and VEGF-E have been shown to bind to NRP1 [42,43], while the VEGFR3 ligands, 
VEGF-C and VEGF-D, interact with NRP1 and NRP2 [44,45]. PlGF-2 also binds to NRP1 
[46]. There is some evidence that other growth factors may bind to NRP1. Thus, FGF-2 binds 
to NRP1 in vitro [47], PDGF-BB has been co-immunoprecipited with NRP1 in VSMC [48], 
NRP1 associates with PDGFRα in VSMC and in mesenchymal stem cells [21,49], and 
colocalises with PDGFRα and enhances PDGF-BB binding affinity in hepatic stellate cells 
[50]. However, definitive evidence for high affinity functional binding of extracellular factors 
other than VEGFs and semaphorins to NRP1 is so far lacking [21,51], and this question 
requires further investigation. 
 
NRP genomic organisation and isoforms 
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The NRP1 gene spans over 120 kb and is composed of 17 exons [52]. The NRP2 gene is > 112 
kb, also comprising 17 exons [52]. Human NRP1 and NRP2 genes map to chromosomal 
positions 10p12 and 2q34, respectively [53]. The strong similarities in the exon-intron 
organisation of the NRP1 and NRP2 genes (Fig. 1), their exon and intron sizes, and positions of 
many of the splices sites suggests that they may have originated from a gene duplication event. 
Alternative splicing results in the generation of several isoforms of NRP1. One membrane-
associated NRP1 isoform has been identified, called NRP1(Δexon16), which lacks the 51 
nucleotides corresponding to exon 16 [52,54]. NRP1(Δexon16) does not differ from the 
common full-length NRP1 in its binding to VEGF165, dimerisation with VEGFR2 or regulation 
of VEGF165 signalling [54]. Four NRP1 mRNA isoforms have so far been reported, all 
predicted to encode soluble proteins containing the a1/a2 and b1/b2 domains but lacking the 
MAM (c), transmembrane and cytoplasmic domains (Fig.1). These isoforms vary in size from 
551 to 704 amino acid residues due to alternative splicing. However, only two soluble NRP1 
(sNRP1) isoforms, s12NRP1 (NRP1 isoform b) and sIVNRP1 (NRP1 isoform c), have so far 
unambiguously been shown to be expressed in protein form. Soluble isoform sIIINRP1 contains 
a1/a2 and b1/b2 domains missing 48 aa at the C terminus of the b2 domain, but contains 13 
extra amino acids resulting from a shift in the reading frame of exon 12 [55]. Isoforms sIIINRP1 
(551 aa) and sIVNRP1 (609 aa) occur in both normal and cancerous human tissues and both 
bind to VEGF165 and Sema3A [55]. Soluble NRP1s may act as decoys, competitively binding 
and sequestering ligands such as VEGF165 and Sema3A, and therefore negatively regulating 
functions mediated by these cytokines. In support of such a role, sNRP1 inhibits tumour cell 
growth in vivo and triggers tumour cell apoptosis, mimicking the effect of VEGF165 withdrawal 
[56]. However, the effects of sNRP1s may be more complex than suggested by a 
straightforward decoy role. Thus, whereas an sNRP1 monomer sequesters VEGF165 and 
inhibits its activity, sNRP1 dimers appear to deliver VEGF165 to endothelial cell VEGFR2, 
thereby promoting angiogenesis [57].  
 
Membrane-bound NRP2 exists in two major isoforms, NRP2a which shares 44% overall 
homology at the amino acid level with NRP1, and NRP2b which is identical to NRP2a in its 
extra-cytoplasmic domain, but exhibits only 11% homology with NRP2a in its transmembrane 
and cytoplasmic regions (see Fig. 1). In the mouse, a total of four NRP2a isoforms are 
generated by alternative splicing resulting in insertion of 0, 5, 17 and 22 (17+5) amino acids 
after residue 809, situated between the MAM and the transmembrane domain [11]. In the 
human, two forms of NRP2a have been cloned, NRP2a(17) and NRP2a(22), homologous to the 
corresponding mouse isoforms. The NRP2a(22) isoform (931 amino acids) results from the 
insertion of the five amino acids GENFK within the 17 amino acid insertion of NRP2a(17) (926 
amino acids; Fig. 1). The NRP2a(0) and NRP2a(5) isoforms have not so far been found in human 
tissues. These isoforms do not appear to differ in their ligand binding properties, but insertion 
of residues between the MAM and transmembrane domains might potentially NRP2’s ability to 
form complexes with VEGFR2 or to homodimerise.  
NRP2b displays little homology with NRP2a after residue 808 [52] with a distinct cytoplasmic 
domain lacking the carboxy-terminal PDZ domain recognition sequence, SEA, required for 
interaction with synectin. Similar to NRP2a, NRP2b(0) and NRP2b(5) isoforms result from 
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alternative splicing and the insertion of zero or five amino acids after amino acid 808. The 
marked differences in their cytoplasmic domains suggest that NRP2a and NRP2b isoforms may 
have divergent functions, a possibility supported by their differential tissue expression. NRP2a 
and NRP2b are both highly expressed in the brain, but NRP2a is preferentially expressed in the 
liver, lung, small intestine, kidney and heart, while NRP2b is present in heart and skeletal 
muscle [52]. A soluble NRP2 isoform is also generated by alternative splicing (see Fig. 1), 
s9NRP2 (1785 bp, 555 aa, 62.5 kDa) consisting of the two a1/a2 domains the b1 domain and a 
truncated b2 domain followed by the 8 amino acids VGCSWRLPL encoded by intron 9 [52]. 
Neuropilin Function in Development 
  
Targeted disruption of genes encoding NRPs and their ligands has demonstrated an essential 
dual role of these molecules in neurogenesis and cardiovascular development (see Table 1). 
NRP1 null mice die between E10.5 and E14.5, dependent on the genetic background, with a 
spectrum of cardiovascular and neuronal defects. Both the central nervous system (CNS) and 
peripheral nervous system (PNS) are severely affected with defects in the homing and 
fasciculation of spinal, cranial and other sensory neurons [5]. Both small and large vessels of 
the yolk sacs are disorganised and the capillary network sparse, while aberrant embryonic 
macrovascular development is characterised by lack of development of the branchial arch, 
related great vessels and dorsal aorta, transposition of the aortic arch, and insufficient septation 
of the truncus arteriosus [6]. NRP1 over-expression also results in embryonic lethality with 
excess capillary growth, haemorrhage in the head and neck and a malformed heart, in addition 
to anarchic sprouting and defasciculation of nerve fibres [58].  Mice with an endothelial-
specific NRP1 deletion also exhibit mid-to-late embryonic lethality, a poorly-branched 
vasculature and multiple defects in the major arteries and defective septation of the major 
cardiac outflow tract [4]. In contrast, knock-in mice expressing a mutant NRP1 with a 7 amino 
acid deletion in the a1 domain required for Sema3A binding but retaining the ability to bind 
VEGF-A, survive to birth, possess no obvious cardiovascular defects, but exhibit aberrant 
pathfinding of sensory afferent nerves to synapses in the CNS and defasciculation of spinal and 
cranial nerves, most of the mice dying by P7. Though it has been proposed that Sema3A and 
VEGF-A interact competitively via NRP1 in cardiovascular development, the analysis of 
different mouse NRP1 mutants indicates that the major developmental functions of NRP1 
reflect tissue-specific actions of either VEGF-A165 binding to NRP1 in the endothelium, or 
Sema3A binding to neuronal NRP1, these two signalling pathways being segregated with 
relatively little cross-talk between the two types of ligand-NRP1 interaction. Thus, the VEGF-
A/NRP1 interaction is thought to be essential for cardiovascular development while the 
semaphorin/NRP1 signalling axis is essential for formation of cranial and spinal nerve 
projections, guidance of peripheral projections of bipolar neurons of the vestibular ganglion 
and the central projections of a subset of axons of cutaneous sensory neurons, and for basal 
cortical neuron dendrite development [4].  
The importance of semaphorin-neuropilin interactions in axonal homing is demonstrated by the 
close similarities of the neuronal pathfinding defects in NRP1 and Sema3A mutant mice 
[4,5,59], and in mice lacking Sema3F and NRP2 [60,61,62-64]. The guidance of motor axons 
from the spinal cord during vertebrate limb bud development serves as a striking illustration of 
how the expression patterns of NRPs and their specific semaphorin ligands exquisitely 
choreograph the homing of specific subsets of axons. As they leave the spinal cord, both lateral 
and medial axons of the lateral motor column (LMCl and LMCm, respectively) express NRP1, 
  8 
 
while NRP2 is restricted to the LMCm; chemorepulsive Sema3A is expressed throughout the 
limb bud whereas Sema3F is localised to the dorsal limb bud. Targeted disruption of either 
NRP1 or Sema3A causes premature and disorganized invasion of the limb bud by motor axons, 
and misprojection of both LMCl and LMCm axons. Deficiency of either Sema3F or NRP2 
results in selective misprojection of LMCm axons, usually expressing NRP1 and NRP2, to the 
dorsal limb, while LMCl axons normally expressing only NRP1 track normally to the dorsal 
limb [62,64]. NRPs do not mediate all functions of their Class 3 semaphorin ligands, however. 
For example, the findings that loss of either Sema3E or plexin D1 causes a similar 
disorganisation of the intersomitic vasculature [65-67], while genetic ablation of NRP1 has no 
such effect, are explained by generation of repulsive cues to endothelial cells as a result of 
Sema3E binding directly to Plexin D1 independently of NRP1. Interestingly, Sema 6D, which 
does not bind NRPs, utilizes a complex between a VEGFR2 co-receptor and plexin A1 to 
mediate signalling essential for cardiac development [68]. 
While these studies indicate that the cardiovascular and neuronal guidance functions of NRP1 
result mainly from spatially distinct and divergent functions of NRP1 expressed in the 
vasculature or neurons, some degree of co-operation between Sema3A and VEGF binding in 
cardiovascular development is supported by the finding that knock-in NRP1 mice deficient in 
Sema3A binding and also null for NRP2 (see Table 1), mice in which VEGF is only able to 
bind to NRP1, exhibit cardiovascular defects similar to those in endothelial-specific NRP1 null 
mice [4]. Furthermore, another class III semaphorin, Sema3C, is required for septation of the 
cardiac outflow tract and thus partially phenocopies the endothelial-specific NRP1 knockout, 
suggesting that an interaction between NRP1 and Sema3C in the endothelium may be 
functionally important. 
In contrast to NRP1 mutant mice, NRP2 null mice survive to adulthood with no obvious 
cardiovascular abnormalities, but exhibit a severe reduction of small lymphatic vessels [69] and 
capillaries, as well as abnormal guidance and fasciculation of cranial and spinal nerves [60,61]. 
Doubly deficient NRP1-/-/NRP2-/- mice exhibit earlier embryonic mortality than the NRP1 
knock out (E8 versus E12-13.5) and have a more severe vascular phenotype resembling the 
VEGF-A165 and VEGFR2 (KDR) knockouts [70], marked by large avascular areas in the yolk 
sacs, and head and trunk regions, and a lack of connections between blood vessel sprouts. 
An essential role of NRP1 in vascular development has also been demonstrated in other 
vertebrate species. In the zebra fish embryo, NRP1a is expressed in the neural tube; NRP1b is 
expressed in the nose and the cranial neural crest cell; NRP2a in the telencephalon and anterior 
pituitary; and NRP2b in the telencephalon, thalamus, hypothalamus, and epiphysis [71,72]. 
Morpholino NRP1 knock down in the developing zebrafish [7] produced a severe vascular 
phenotype characterized by a loss, or anarchic sprouting, of new capillaries from pre-existing 
intersomitic vessels, but had no effect on the formation of the major axial vessel, suggesting 
that, in zebrafish, NRP1 is not implicated in vasculogenesis [7]. Defects were also observed in 
the developing zebra fish nervous system after NRP1 knockdown, characterized by aberrant 
migration and branching of motor neurons [73,74]. 
 
NRP expression may also play an important role in the early specification of arterial and 
venous fate during vascular development. In one day old chick embryos, NRP1 and NRP2 are 
co-expressed in the early extra-embryonic blood islands, but by the 13 somite stage expression 
of NRP1 and NRP2 has become restricted to, respectively, the arterial and venous regions of 
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the primary vascular plexus before blood has started to flow [75]. In 26-somite embryos, which 
have a functioning vasculature, NRP1 and NRP2 are differentially expressed in arteries and 
veins, while the NRP2 ligand, Sema3F, was bound to NRP2-expressing cells [75,76]. Similar to 
the expression patterns in the chicken embryo, NRP1 is preferentially expressed in the dorsal 
aorta of zebra fish embryos, and NRP2 transcripts are localised to the posterior cardinal vein 
[77]. It is unclear at present whether differential NRP expression is crucial for the early 
embryonic segregation of arterial and venous cells in mammalian embryos, though the 
relatively mild phenotype in NRP2-deficient mice (Table 1), suggests that NRP2 expression 
may be less important in this respect. 
 
Receptors and Signalling Mechanisms 
 
NRPs are not thought to be able to transduce a biological signal or response in the absence of 
another signalling receptor, but rather to function as co-receptors that bind extracellular ligands 
with high affinity and complex with other transmembrane molecules (eg VEGFR2 or plexins) 
to form a heterocomplex or holoreceptor. However, this model does not fully or easily explain 
all the evidence relating to the functions of NRPs in endothelial cells and other cell types. 
NRP1 has been demonstrated to associate with at least one intracellular PDZ protein, synectin, 
raising the possibility that NRPs may be able to modulate intracellular signalling through 
protein-protein interactions. 
 
Plexins 
 
NRP1 mediates the chemorepulsive effects of Sema3A, but does so by acting as the 
ligand-binding module of a complex or holoreceptor between NRP1 and specific members of a 
family of transmembrane receptors called plexins [78-80]. NRPs 1 and 2 form complexes with 
several plexins independently of the presence of semaphorins, including plexins A1, A2, A3 
and B1 [79-81]. The human plexin gene family comprises nine members divided into four 
subfamilies: four plexin As (1 to 4), three plexin Bs (1 to 3), plexin C1 and plexin D1 [36]. 
Plexins are large transmembrane receptors with extracellular regions comprising a Sema 
domain (homologous to sema domains in Semaphorins), two or three cysteine-rich regions 
called Met-related sequences (MRS) domains also found in the MET oncogene family, and 
three or four immunoglobulin-like domains shared by plexins and transcription factors (IPT), a 
transmembrane domain, and an intracellular region containing two conserved regions, the 
functions of which are not yet clearly defined, but show some homology to ras GTPase-
activating protein (GAP) domains, and which, in the case of Plexin B1, has been shown to act 
as a GAP for R-Ras [82].  
Sema3A contains both a NRP binding site, and potential sites of interaction with Plexins. 
Antipenko et al have proposed a model based on the crystal structure of the Sema3A Sema 
domain and mutagenic analysis, in which Sema3A binding results in a 2:2:2 complex between 
Sema3A, plexin A1 and NRP1, and involving relief of autoinhibition of plexin A1 [83]. This 
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has been proposed to cause activation of the plexin intracellular domain and the transduction of 
signals essential for chemorepulsion. Deletion of the cytoplasmic domain of NRP1 did not 
impair sema3A signalling [18], indicating that neuropilins may function solely as the binding 
entity of the complex while plexins mediate signalling. 
The cytoplasmic domain of plexins is responsible for downstream signalling induced by 
semaphorins and resulting in the collapse of neurons [78-80]. Monomeric GTPases of the Rho 
family are thought to play a key role in regulating actin-based motility in neuronal cells [83], 
and have been implicated in semaphorin-mediated growth cone collapse [84,85]. Recruitment 
of the small GTPase Rnd to the cytoplasmic Plexin A1 domain triggers cytoskeletal collapse, 
but this effect is antagonized by RhoD which is also able to bind to Plexin A1 but blocks 
repulsion of sympathetic neurons [86]. Sema3A-induced cytoskeletal collapse in Cos-7 cells 
was dependent on co-transfection of Plexin A1 and NRP1, required activation of Rac, but not 
Rho, and involved a direct interaction between Rac and the plexin A1 cytoplasmic domain [87-
89]. If and how NRP1 regulates Plexin-dependent signalling through small GTPases is unclear. 
 
L1 CAM 
 
The immunoglobulin superfamily cell adhesion molecule, L1, is also a potential partner for 
NRP1 in mediating chemorepulsive Sema3A signals. L1-deficient mice are smaller, less 
sensitive to touch and pain, and exhibit lack of hind limb coordination compared to littermate 
controls, and display a striking reduction in the size of the corticospinal tract and in the 
association of Schwann cells with axons, [90]. That at least part of the phenotype in these mice 
results from defective axonal guidance orchestrated by Sema3A, is suggested by the inability of 
Sema3A to repel L1-deficient cortical axons [91], and the formation of stable complexes of L1 
and NRP1 mediated by interactions between their extracellular domains [92]. NRP2, which is 
not required for Sema3A signalling, was unable to associate with L1-CAM [92]. Several L1 
mutations located in the NRP1 binding region are associated with some human neurological 
disorders, including X-linked hydrocephalus and MASA syndrome (Mental retardation, 
Aphasia, Shuffling gait, Adduced thumbs). Interestingly, one such mutation, L120V, also 
disrupts L1 association with NRP1, suggesting a causal role of defective L1/NRP1 signalling in 
human neurological disease [92]. Soluble L1 extracellular domain is able to convert repulsive 
Sema3A signals into chemoattraction by binding in trans to NRP1 and this conversion is 
mediated by nitric oxide-dependent activation of guanylate cyclase and consequent cyclic GMP 
synthesis [92], reminiscent of the role of asymmetric guanylate cyclase distribution in 
determining chemoattractant properties of Sema3A in cortical apical dendrites [93]. The effects 
of L1 deficiency do not phenocopy the neural defects of Sema3A-deficient mice or NRP1sema3A-
/- mice expressing mutant NRP1 unable to bind Sema3A, indicating that L1 regulates Sema3A 
signalling via NRP1 in a more restricted set of neurons. It is also unclear yet whether the 
L1/NRP1 complex is either distinct from, or linked with, the plexin/NRP1 holoreceptor. 
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VEGF signalling 
In the endothelium, NRP1 is thought to function primarily as a co-receptor for the VEGF 
receptor tyrosine kinase (RTK), VEGFR2 (KDR in humans, Flk-1 in mice). NRP1 enhances 
VEGF binding to VEGFR2, VEGFR2 phosphorylation, and VEGF-induced signalling and 
migration [94-97], and NRP1 and VEGFR2 associate to form a heterocomplex or 
‘holoreceptor’ [33,37,95-99]. NRP1 is not required for VEGFR2 activation, and it is unclear 
whether NRP1 complexation with VEGFR2 increases the intrinsic affinity of VEGFR2/KDR 
for VEGF-A [33, 95, 100]. However, siRNA-mediated NRP1 knockdown resulted in a 50% 
inhibition in VEGFR2 phosphorylation at Tyr 1175 [101,102], a residue required for VEGFR2-
mediated activation of phospholipase C-γ/ERK, cell proliferation and normal embryonic 
development. It is also important to emphasise that NRP1-dependent VEGF signalling also 
requires active VEGFR2 [101]. NRP1/VEGFR2 complexation is enhanced by VEGF binding 
[94,96,102], though some studies have reported constitutive VEGF-A-independent complex 
formation [95,100]. VEGF-induced NRP1 association with VEGFR2 is likely to result from the 
dual binding of the cysteine knot motif of VEGF-A165 in the core VEGF homology region to 
VEGFR2, and of the exon 7/8 encoded carboxy-terminal moiety of VEGF-A165 to the b1 
domain of NRP1 bridging between the receptors to form a tripartite complex. Deletion of the 
NRP1 carboxy-terminal PDZ domain binding motif decreased NRP1/VEGFR2 co-
immunoprepcipitation [103], suggesting that intracellular interactions are also important for 
heterocomplex formation, though it is unclear whether this involves a direct physical 
interaction between the NRP1 cytosolic domain and VEGFR2. 
Some essential functions of VEGF, including cell survival and proliferation, appear to be 
largely independent of NRP1. This is illustrated by the findings that activation of the 
phospholipase C-γ/ERK and Akt pathways, which play major roles in proliferation and survival 
functions of VEGF, are largely unaffected in the absence of NRP1 or when VEGF binding to 
NRP1 is selectively inhibited [37,94,101-104,]. Moreover, VEGF-A165 and the VEGF-E-NZ2 
subtype, which both bind VEGFR2 and NRP1, induced similar increases in PLC-γ tyrosine 
phosphorylation and activation of ERK and Akt as VEGF121, which is unable to promote 
VEGR2/NRP1 complexation, but exhibited greater angiogenic activity and stimulated more 
p38 kinase activation than VEGF-A121 [105]. However, a study of VEGF-A signalling in 
mouse endothelial cells expressing NRP1 lacking its cytoplasmic domain indicates that NRP1 
is important for VEGF-A ERK signalling [106], an effect which is consistent with the reduction 
in VEGFR2 Y1175 phosphorylation caused by NRP1 knockdown [101,102]. Recent studies 
also indicate an important role for NRP1 in mediating VEGF-induced tyrosine phosphorylation 
of p130Cas, an adapter protein with a key role in regulating actin filament dynamics and cell 
migration [20,21,101,102,107]. P130Cas associates with several other signalling molecules 
involved in regulating cell migration and actin cytoskeleton organisation, including the related 
non-receptor tyrosine kinases, Focal adhesion kinase (FAK) and Pyk2. Interestingly, though 
VEGF stimulation of p130Cas tyrosine phosphorylation was mediated via Pyk2 [101], NRP1 
knockdown did not affect FAK tyrosine phosphorylation at its major autophosphorylation site, 
Y397. However, both NRP1 knockdown and expression of a NRP1 Y297A mutant deficient in 
VEGF binding, blocked VEGF-induced FAK tyrosine phosphorylation at Y407 [102], a site 
that is regulated by Pyk2 [108]. These findings (summarised in Fig. 3) suggest that NRP1 
selectively mediates VEGFR2 signalling via a Pyk2/p130Cas pathway important for cell 
migration. Mice deficient in p130Cas die in utero primarily from cardiovascular defects, and 
exhibit impaired actin filament assembly; p130Cas also appears to be expressed predominantly 
in the cardiovascular system at the time in embryonic development that lethality occurs in 
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p130Cas-null mice [109]. These findings are suggestive of a link between NRP1 and p130Cas 
signalling which may play an important role in developmental angiogenesis.  
Recent studies have highlighted the role of NRP1 in endocytosis and intracellular trafficking. 
VEGF-A165 induced clathrin-dependent NRP1 endocytosis, whereas semaphorin 3C (sema3C) 
stimulated endocytosis via a distinct pathway sensitive to the cholesterol-depleting compound 
methyl β-cyclodextrin, which is thought to selectively disrupt lipid rafts [110]. NRP1 
trafficking in response to both VEGF-A165 and Sema 3C was significantly slower in endothelial 
cells lacking synectin, and synectin-/- endothelial cells also lacked a chemorepellent response to 
Sema3C, suggesting that Semaphorin-induced NRP trafficking is essential for relay of 
chemorepulsive cues. Other work suggests that NRP1 endocytosis may also be important for 
VEGF signalling in arteriogenesis (discussed below).   
In contrast to the well-defined signalling role of VEGFR2 in VEGF angiogenic activity, the 
function of VEGFR1 has not been fully characterised. The VEGFR1 knock out is lethal [111], 
but a normal phenotype is observed in transgenic mice with Flt-1 lacking the intracellular 
domain [112]. These findings indicate that VEGFR1 plays a decoy function by sequestering 
VEGF and therefore limiting its availability for binding to VEGFR2. NRP1 has been found to 
bind in vitro to the VEGFR1/Flt-1 extracellular immunoglobulin-like domains 3 and 4 [41], and 
it is possible that such a complex may compete for VEGF binding to VEGFR2/NRP1 
heterodimers.  
Recent findings indicate that VEGF-C interacts with NRP2 in a mainly heparin-independent 
manner, whereas VEGF-D binding to NRP2 is heparin-dependent [45]. Moreover, VEGFR3 
and NRP2 co-localised and co-internalised following stimulation by VEGF-C and -D [45]. The 
formation of complexes between NRP2 and VEGFR2 or VEGFR3 resulted in a lowering of the 
activation threshold of VEGFR2 and an enhancement of cell survival and migration induced by 
VEGF-A and the VEGFR3 ligand, VEGF-C [113]. VEGFR3 and VEGF-C are both strongly 
implicated in lymphatic vascular development [114], and complex formation between VEGFR3 
and NRP2 may help to explain the involvement of NRP2 in lymphangiogenesis as suggested by 
the phenotype of NRP2 knock out mice [69; Table 1]. Co-immunoprecipitation of cross-linked 
125I-VEGF also revealed the existence of a NRP2/VEGFR1 complex [115], but the biological 
relevance of such a complex is not clear. 
 
Role of the NRP cytosolic domain 
 
While there is strong evidence that NRP1 functions primarily as a co-receptor without 
an independent signalling role, some findings suggest that NRPs have functions that are not 
dependent on the known NRP ligands and interacting receptors, and further raise the possibility 
that NRP1 is able to support functional cellular signalling. For example, VEGF elicits 
biological responses in some cell types that are NRP-positive but express little or no KDR, such 
as VSMC [116] and some cancer cells (see below). Antibodies that selectively block VEGF 
binding to NRP1 have synergistic effects on cencer growth in combination with function-
blocking antibodies directed against VEGF [37,94,101], suggestive that NRP1 has VEGF-
independent roles at least in tumour vascularisation. The cytoplasmic domains of NRP1 and 
NRP2 contain a carboxy-terminal consensus PDZ binding motif that associated with the PDZ 
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protein, synectin or GIPC1 (RGS-GAIP-interacting protein-1), in a yeast two-hybrid screen 
[12]. A functional role for NRP1 association with synectin in angiogenesis is supported by the 
finding that expression of NRP1 lacking the C-terminal SEA motif disrupted vessel formation 
in zebrafish, and that knockdown of either synectin or NRP1 in zebra fish produced similar 
vascular phenotypes [117]. Furthermore, synectin was found to associate with NRP1 in human 
endothelial cells, and synectin knockdown inhibited NRP1-mediated endothelial migration 
[117]. In contrast, the C-terminal PDZ-binding domain does not appear to be important for 
Sema3A-mediated neuronal pathfinding functions of NRPs [18]. 
 Synectin/GIPC was originally found to associate with one of the regulators of G protein 
signalling (RGS) proteins, called RGS19 (also known as GAIP) [118]. The GIPC/RGS19 
complex is anchored to the cell membrane, localises to clathrin-coated vesicles and has been 
implicated in endocytosis and intracellular membrane trafficking [119]. Synectin/GIPC binds to 
G protein coupled receptors and modulates their signalling [119], and can also interact with up 
to twenty other proteins, including the proteoglycan, syndecan-4 [120], integrin α5 and α6 
subunits [121], the transmembrane semaphorin, M-SemaF [122], and rho GEF (rho guanine 
exchange factor or syx1) [123]. These findings suggest that synectin has the potential to 
participate in multimeric protein complexes or scaffolds able to link surface receptors and 
integrins with intracellular signalling networks. In vivo studies show the importance of synectin 
in the development of a functional vascular system in both the zebrafish and the mouse [124]. 
Synectin deficient mice are viable, but the mice are smaller than littermate controls, and have a 
significantly reduced number of small arteries, resulting in impaired vascular functions. 
Arterial cells from synectin-/- mice exhibited reduced angiogenic and endothelial responses in 
cell culture models, and aberrant cellular distribution of rac1 [124]. The mainly microvascular 
arterial defects in synectin knockout mice do not phenocopy the embryonic lethality or aberrant 
macrovascular development of either global or endothelial-specific NRP1 deficiency, 
indicating that not all developmental functions of NRP1 are dependent on synectin association. 
However, it is possible that other related molecules, such as GIPC2 or GIPC3, may compensate 
for loss of synectin [125].  
 A mutant mouse line with a knock-in of NRP1 lacking the cytoplasmic domain 
(NRP1Cyto) has recently been reported. NRP1Cyto mice are viable, fertile, appear phenotypically 
normal, and also exhibit normal developmental vasculogenesis and angiogenesis. However, 
they display a restricted phenotype characterised by an abnormally high incidence of crossing 
of arteries and veins in the retina similar to the increased arteriovenous crossings observed in 
the human eye disease, branch retinal vein occlusion [126]. These mice also displayed a 
significant decrease in the number of smaller arteries and arterioles in the kidney, heart and 
hindlimb vasculatures at P7 and in adults compared to control animals, differences that were 
concomitant with small reductions in whole body, kidney and heart size [106]. These 
phenotypic effects of deletion of the NRP1 cytoplasmic domain have similarities to those of 
synectin deficiency described above, lending support to the concept that a role of NRP1 in 
developmental and adult arteriolar growth and maturation could be mediated specifically via 
interaction of the cytolplasmic domain of NRP1 with synectin. Lanahan et al further showed 
that lack of the NRP1 cytoplasmic domain results in delayed VEGFR2 trafficking, one 
consequence of which is impaired VEGFR2 phosphorylation at Y1175, a site critical for 
mediating VEGF-A-induced ERK activation [106]. These findings suggest that the NRP1 
cytoplasmic domain may be crucial for normal endocytosis of VEGFR2, and that NRP1-
dependent VEGFR2 trafficking plays a key role in intracellular signalling important for 
arteriolar morphogenesis in development and post-natal organ growth.  
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The role of NRP1 in endothelial cell function may also be mediated by interactions with 
integrins. An association between NRP1 and the cytoplasmic domain of the β3 integrin subunit 
negatively regulates angiogenesis by limiting availability of NRP1 for complexation with 
VEGFR2 [127]. An interaction between NRP1 and the major fibronectin receptor, integrin 
α5β1, is reported to mediate α5β1 endocytosis and regulate endothelial cell adhesion to 
fibronectin [128]. The NRP1 cytosolic domain was required for α5β1 endocytosis possibly due 
to interaction between the SEA motif and synectin, but did not appear to be necessary for 
association between NRP1 and α5β1. NRP1 association with β1 integrin is also implicated in 
pancreatic cancer cell growth, survival and invasion [129]. 
 
 
NRP regulation of cell migration 
 
The most characteristic biological function mediated by NRPs in neuronal cells is 
chemorepulsion. NRP1 is essential for mediating Sema3A stimulation of growth cone collapse 
and axon repulsion in DRG neuronal cultures [26,130], while NRP2 is responsible for Sema3F-
induced repulsion of superior cervical ganglia [11,131]. Sema3A and 3F have also been 
reported to promote chemorepulsion in porcine aortic endothelial (PAE) cells expressing, 
respectively, NRP1 and NRP2 [132,133], and in human endothelial cells [134-136], though 
other investigators failed to find an inhibitory effect of Sema3A on endothelial cell migration 
[94]. Sema3A also appears to be required for the correct orientation and chemoattraction of 
cortical apical dendrites [93]. This chemoattractant role of Sema3A is mediated at least in part 
via NRP1, as judged by the effects of function-blocking NRP1 antibody. The conversion of the 
Sema3A/NRP1 axis from chemorepulsion to chemoattraction is determined by the distribution 
of soluble guanylate cyclase: guanylate cyclase is localised to the dendrite, and inhibition of 
either guanylate cyclase or protein kinase G disrupted dendrite outgrowth in response to 
Sema3A [93,137]. 
Much evidence points to a role of NRP1 in directed endothelial cell migration or chemotaxis. 
Co-expression of NRP1 and VEGFR2 in PAE cells enhances VEGF binding and chemotaxis 
[33], and NRP1 mediates endothelial cell attachment to extracellular matrix [138]. VEGF-A165 
also stimulates morphogenetic responses in renal epithelial cells, including sheet migration and 
tubulogenesis, through a mechanism dependent on VEGFR2 and which is also blocked by 
either neutralizing antibody to NRP1 or by the chemorepulsive NRP1 ligand, Sema3A [139]. 
Antibodies which specifically block VEGF binding to NRP1, inhibited the migratory response 
to VEGF, in vitro endothelial cell sprouting, and neovascularisation in vivo [94]. Interestingly, 
the same study reported that blocking NRP1 antibodies prevent pericyte recruitment to new 
vessels in mouse neonatal retinal vascularisation and tumour vascularisation models, 
suggesting a role of endothelial NRP1 in the maturation and stabilisation of developing vessels. 
The cellular mechanism underlying such a role of NRP1 is unclear, but could occur via one or 
both of two mechanisms, one in which endothelial NRP1 is important for adhesion or 
chemoattraction of pericytes to developing vessels, and/or a role for NRP1 expressed in 
pericytes or VSMC in adhesion and migration of these cells [94]. NRP1 is highly expressed in 
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human aortic and coronary artery smooth muscle cells (HCASMC), both as a core protein of 
130 kDa and as a high molecular weight species modified by O-linked glycosylation [19-21]. 
Inhibition of NRP1 function significantly decreases the migratory response of VSMCs to 
PDGF-BB and PDGF-BB signalling via p130Cas, similar to findings in endothelial cells [21]. 
In support of a functional role of NRP1 in VSMC in vivo, apart from neurons, epicardium and 
endothelium, NRP1 is reported to be most strongly expressed in late mouse embryos in the 
VSMC of large vessels [140]. Proteoglycans play important roles in VSMC in vivo, and it is 
possible that the CS-GAG modification of NRP1 in VSMC may play a role in migratory 
functions of this molecule in developing or remodelling arteries. However, there remains a lack 
of information regarding expression of NRP1 in arterial VSMC in vivo either during 
development or in adult vessels, and determination of a biological role of NRP1 in VSMC will 
await analysis of appropriate animal models. Interestingly, NRP2 is expressed in mouse bladder 
and gastrointestinal smooth muscle in vivo, and increased bladder smooth muscle cell 
contractility was reported in NRP2-deficient mice [141], indicating a novel functional role of 
NRP2 in visceral (non-vascular) smooth muscle cell function in vivo. 
Analysis of vascularisation in mutant NRP1 mice indicate that this molecule plays a key role in 
the guidance of specialized endothelial tip cells in newly sprouting vessels [27]. Tip cells are 
highly polarised cells with abundant filopodia at the migrating edge, studded with VEGRF2, 
and are responsive to gradients of VEGF-A. NRP1-deficient mice exhibit defective endothelial 
cell migration whereas endothelial proliferation appears unaffected in these mice [142,143]. 
NRP1 expression is also downregulated by the Notch signalling pathway, which plays a key 
role in suppressing the tip cell phenotype [144]. These findings do not necessarily indicate that 
NRP1 is essential for endothelial cell migration per se, but rather that NRP1 and its ligand 
VEGF specify the trajectories of migrating cells, similar to its pathfinding and homing role in 
neuronal patterning. 
 
Other cell functions 
 
Several studies indicating a role for NRP1 in cell adhesion to the extracellular matrix, are 
suggestive that such a role of NRP1 may be independent of known ligand interactions 
[102,138,145]. Shimuzu et al. found that recombinant NRP1 proteins supported adhesion of a 
variety of cell lines, including L cells, HEK293T, COS-7, HeLa, p19, KB and NIH3T3, and 
identified specific regions in the NRP1 b1 and b2 domains for adhesion, but showed that 
neither Sema3A nor VEGF-A165 interfered with this activity [145]. Furthermore, siRNA-
mediated NRP1 knockdown disrupted endothelial cell adhesion to fibronectin, laminin or 
gelatin, while silencing of VEGFR2 had little effect, suggesting that an NRP1-mediated 
adhesive function is independent of VEGF-A signalling through VEGFR2 [138]. Blocking 
NRP1 antibodies appeared to have no effect on adhesion of endothelial cells to fibronectin [94], 
consistent with the independence of any adhesive function from VEGF binding. 
NRP1 is also implicated in regulating endothelial permeability. Sema3A induced vascular 
permeability in vivo, an effect that was inhibited in adult mice with a conditional deletion of 
endothelial NRP1, or in wild-type mice treated with a blocking antibody directed against NRP1 
[146]. Transendothelial resistance of PAE expressing VEGFR2/KDR and NRP1 was decreased 
in response to VEGF165 treatment compared to cells expressing either receptor alone, and 
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inhibition of NRP1 in human pulomanry artery endothelial cells decreased VEGF165-induced 
increased permeability [147] 
 
Neuropilin Functions in Disease and Adult Tissues 
 
Cancer 
 
NRP1 and NRP2 are expressed by a wide variety of human tumour cell lines and diverse 
human neoplasms [8,10,33], and are implicated in mediating effects of VEGF and Semaphorins 
on the proliferation, survival and migration of cancer cells [148-151]. Over-expression of 
NRP1 in Dunning rat prostate AT2.1 carcinoma cells increased tumour growth in vivo [150], 
while NRP1 knockdown using siRNA inhibited breast carcinoma cell migration [152], and a 
peptide targeted to the VEGF binding site of NRP1 induced breast tumour cell apoptosis [153]. 
Furthermore, NRP1 plays a role in mediating or potentiating PDGF-BB and HGF/Scatter factor 
signalling through their receptor tyrosine kinases in both glioma and pancreatic cancer cell 
lines, regulating tumour progression, migration and invasion [20,101,154,155]. NRP1 is 
expressed in patient specimens from lung, breast, prostate, pancreatic and colon carcinomas, 
but not in corresponding normal epithelial tissues [22,156-161]. NRP1 has also been found in 
several other tumours including melanoma [162], astrocytoma [163] and neuroblastoma [164]. 
NRP2 expression was reported in lung cancer [156,157], neuroblastoma [164], pancreatic 
cancer [165], osteosarcoma [166] and bladder cancer [167]. It has been suggested that NRP1 is 
more prevalent in carcinomas (mainly of epithelial origin), whereas NRP2 may be more 
frequently expressed in non-carcinoma neoplasms such as melanomas, leukaemias and 
neuroblastomas [10,168,169]. However, there appears no sharp distinction between the types of 
neoplasms expressing NRPs 1 and 2, and often they are co-expressed in tumour cells. 
Furthermore, different cell lines derived from the same tumour types, such as glioma [170], 
may exhibit divergent patterns of NRP1 and NRP2 expression. 
Clinical studies suggest that NRP1 plays a role in tumour growth and disease progression 
[8,10]. Overexpression of NRPl has been demonstrated to be associated positively with the 
metastatic potential, advanced stage and clinical grade of prostate carcinoma [159]. NRP1 
upregulation in gastrointestinal carcinomas appears to correlate with invasive behavior and 
metastatic potential [171]. Co-expression of NRP1 and NRP2 also increased in the progression 
from dysplasia to microinvasive lung carcinoma, and correlated significantly with tumour 
progression and poor prognosis in patients with non-small cell lung carcinoma [156]. NRP1 
also appears to be preferentially expressed in metastatic cells, and is found, for example in the 
metastatic breast cancer MDA-MB-231 and melanoma MDA-MB-435 cell lines but not in the 
nonmetastatic cell line MDA-MB-453 or some nonmetastatic tumours [33,148]. 
While most studies have indicated a pro-tumourigenic role of NRPs, some reports suggest that 
NRP1 plays a more complex role in some tumour types. Thus, NRP1 over-expression in Panc-1 
cells was found to reduce tumour volume and incidence [172], whereas the same group showed 
that FG pancreatic carcinoma cells expressing NRP1 have increased resistance to anoikis and 
cytotoxic drugs [173]. Furthermore, some findings suggest that not all effects of VEGF in 
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tumour cells may be dependent on NRP1. Lee et al found that survival effects of VEGF in the 
breast carcinoma MDA-MB-231 and MCF-7 cell lines were mediated by internally expressed 
VEGFR1/Flt1, and were unaffected by NRP1 knockdown [174].  
There is also some evidence pointing to potentially differential or antagonistic roles of 
NRP1 and NRP2 in tumour cell regulation. Sema3F, the best-characterised ligand for NRP2, 
induces a poorly vascularised non-metastatic phenotype in melanoma xenografts in mice [133] 
and, suggestively, Sema3F and a second NRP2 ligand, Sema3B, are both localised to the 
3p21.3 chromosomal region, which is commonly deleted in human lung cancers [175,176]. 
These findings suggest that Sema ligands for NRP2 are potential tumour suppressors. 
Confirmation of such an anti-tumourigenic role of NRP2 awaits further work. 
Recent studies provide direct evidence that NRP1 contributes to tumour cell growth and tumour 
neovascularisation in vivo. A peptide that inhibits VEGF binding to NRP1 has been reported to 
inhibit angiogenesis and growth of tumour xenografts [177]. An antibody targeted to the b1 
domain that specifically blocks VEGF-A binding to NRP1 causes a range of effects in 
endothelial cell cultures including inhibition of VEGFR2 complex formation, VEGF-induced 
migration, and vascular sprouting, reduces angiogenesis in a neonatal retinal neovascularisation 
model, and inhibits tumour growth and tumour vascularisation in mouse xenograft models. 
Blocking NRP1 antibody alone had a relatively small effect on tumour growth, but produced a 
strong additive effect when used in combination with the blocking VEGF antibody, 
bevacizumab or Avastin [94], now approved for clinical use in patients with late stage 
colorectal carcinoma. Interestingly, Pan et al reported that the anti-tumour activity of blocking 
NRP1 antibodies was not dependent on NRP1 expression in the tumour cell line used in the 
xenograft model. Furthermore, this study also found no evidence of direct effects of NRP1 
antibodies on tumour cell proliferation, suggesting that their anti-tumourigenic effects were 
mainly due to inhibition or destabilisation of the tumour vasculature. High expression of NRP1 
is reported to correlate with poor overall survival in patients with Medulloblastoma, the 
commonest pediatric malignant brain tumour [178]. Furthermore, inhibition of either NRP1 and 
the NRP1 ligand PlGF in mice results in medulloblastoma regression, decreased metastasis, and 
increased overall survival. Interestingly this study reports that PlGF derived from tumour 
stromal cells acts through NRP1 and independently of VEGFR1 to promote tumor cell survival.  
Another approach to targeting NRP1 therapeutically in cancer is to use small molecule 
antagonists of the ligand interaction with the NRP1 extracellular domain. A peptidomimetic of 
the exon 8-encoded region of VEGF165, EG00229, was designed on the basis of structure 
activity relationship analysis of the bicyclic peptide, EG3287, corresponding to the C-terminal 
28 VEGF165 amino acid residues. EG3287 and EG00229 inhibited VEGF-induced VEGFR2 
phosphorylation and endothelial cell migration and enhanced the in vitro cytotoxic effect of 
paclitaxel and 5-fluorouracil in cancer cells [16,151]. Small molecule inhibitors of NRP1 have 
potential as novel anti-cancer therapeutics. 
The concept that the role of NRP1 in tumour growth is exclusively or even largely confined to 
its contribution to tumour vascularisation or to VEGF signalling in endothelial cells is being 
challenged by recent work which provides new insights into the role of NRP1 in cancer. One 
such development highlights the role of NRP1 in the cancer stem cell niche. Human CD133+ 
glioma stem-like cells (GSC) express VEGFR2 and NRP1 and together these receptors mediate 
the autocrine survival and growth of these cells dependent on GSC-derived VEGF-A [179]. It 
has been proposed that such self-renewal of GSC may explain to modest effects of anti-VEGF 
therapy (bevacizumab) in clinical studies of Glioblastoma multiforme and to resistance to 
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bevacizumab after an initial response. A VEGF-VEGFR2-NRP1 signalling axis has also been 
implicated in generating a perivascular niche for proliferation of cancer stem cells in squamous 
cell skin tumours [180]. NRP1 was expressed in cancer stem cells from skin papillomas 
induced by chemical carcinogenesis in mice, and mice with a conditional NRP1 deletion 
specifically in the epidermis did not develop skin papillomas induced by 25 weeks of phorbol 
ester treatment compared with skin papillomas in 100% of control mice. In this model VEGF 
plays a dual role, stimulating angiogenesis via VEGFR2 expressed on endothelial cells, and 
promoting CSC proliferation via NRP1 expressed on CSC. 
Another challenge to the paradigm of NRP1 acting in cancer primarily as a mediator of VEGF-
driven tumour vascularisation has come from studies of regulatory T cells (T regs), a subset of 
the T cell repertoire that plays an important role in negatively regulating the anti-tumour 
immune response. Several studies have found that NRP1 is highly expressed on T regs positive 
for Foxp3 and CD4 in mice [181,182]. Furthermore, mice with a T cell-specific deletion of 
NRP1 display impaired melanoma growth accompanied by a marked reduction in tumour-
infiltrating Foxp3+ T regs and a concomitant augmentation in activity of effector CD8+ T cells 
[183]. This study also reported that tumour-derived VEGF together with NRP1 expressed in T-
cells are important for chemotactic recruitment of Foxp3+ T regs to tumours. These findings 
suggest a novel role for NRP1 in T regs in suppressing the anti-tumour immune response 
mediated effector T cells. While aspects of the mechanism underlying this role of NRP1 remain 
to be clarified, it appears that NRP1 does not directly mediate the suppressive effect of Foxp3+ 
T regs on effector T cells, but functions mainly in the recruitment of T regs to the tumour 
microenvironment. It is at present unclear whether NRP1 is involved in infiltration of T regs 
into human tumours, and this should be an important goal of future research in this area.  
 
Immune system 
 
NRP1 was found to be expressed in naïve T-cells and immature dendritic cells (antigen 
presenting cells), cell types that interact during the primary immune response in the secondary 
lymphoid organs [184], and are essential for triggering the proliferation and differentiation of 
mature T cells that will later interact again with antigen presenting cells to mediate antigen 
elimination [12]. NRP1 expressed on naïve T cells also mediated their clustering with NRP1-
expressing Cos-7 cells, and the stimulation of resting T cell proliferation by dendritic cells was 
reduced by around 50% by blocking NRP1 antibodies [184]. T cell activation was also reduced 
by Sema3A [185,186]. NRP1 distribution in T cells was polarised, and NRP1 co-localised with 
the T cell marker, CD3, at the interface between dendritic cells and naïve T-cells [184]. While 
the biological relevance of these findings for the immune response in vivo is unclear, they are 
consistent with the formation of homophilic NRP1 interactions between dendritic cells and 
immature T cells, which contribute to an early step in formation of the immunological synapse, 
essential for T cell maturation [184]. As mentioned above, among T cell lineages, at least in 
mice, NRP1 is predominantly expressed in Foxp3+ CD4+ T regs, and it has been shown that 
NRP1 increases the longevity of interactions between T regs and immature dendritic cells, 
enhancing antigen sensitivity [182]. It has been proposed that in the absence of inflammatory 
stimuli, this may confer an advantage of T regs over naïve helper T cells, resulting in enhanced 
suppression of the immune response. Recent findings show that NRP1 is expressed in mice at 
high levels on natural (n) T reg cells that arise in the Thymus, but is present at a low level in 
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induced or adaptive T regs (iTregs) generated in peripheral tissues through induction of Foxp3 
[187,188]. However, Weiss et al reported that in some highly inflammatory settings, such as 
the spinal cords of mice with spontaneous autoimmune encephalomyelitis (EAE) and the lungs 
of mice with chronic asthma, iT regs can express NRP1 [188]. NRPs 1 and 2 have also been 
detected on human basophils, VEGF165 stimulated basophil chemotaxis [189]. 
 
Wound healing 
 
There is evidence that NRP1 is upregulated in response to tissue injury and may be involved in 
regeneration and repair [10]. In Xenopus when the optic nerve was crushed and allowed to 
regenerate, the level of NRP1 increased and remained elevated for weeks before finally 
declining after healing [3]. NRP1 was also found to be strongly expressed in the neovasculature 
during wound angiogenesis in a murine model of dermal wound healing, while blocking anti-
NRP1 antibody reduced wound vascularisation [190]. Optic nerve injury in a rat model resulted 
in cell invasion at the site of injury by microglia, oligodendrocytes, and astrocytes associated 
with induction of semaphorin 3A and NRP1 [191]. NRP1 may protect neuronal cells against 
damage resulting from stress or injury. Thus, IFNγ activation of microglia, a cell type that 
becomes activated following neuronal injury, caused upregulation of NRP1 and plexin A1 and 
was associated with induction of microglial apoptosis by Sema3A, suggesting that a NRP1-
mediated pathway may protect neurons against damage caused by activated microglia [192]. 
Expression of NRPs, VEGFs and Class III semaphorins are also upregulated by cerebral 
ischemic injury in different animal models [193-201]. For example, in a mouse model of 
cerebral ischemia, NRP1 mRNA expression increased rapidly and remained elevated for at 
least a month after the ischaemic event [193]. Interestingly, NRP1 was not only localised to the 
ischemic neurons but also to the endothelial cells of the brain vessels. These findings are 
suggestive of a dual role for NRP1 in the response to cerebral injury, in the promotion of both 
neuronal growth and cerebral angiogenesis.  
 
Liver Cirrhosis 
 
NRP1 upregulation was observed in activated Hepatic stellate cells (HSCs) in two rat models of 
liver fibrosis, and was detected in human biopsies of liver cirrhosis caused by both hepatitis C 
and steatohepatitis [50]. Analysis of PDGF/PDGFRβ– and TGFβ-mediated signalling in HSC 
showed that NRP1 knockdown inhibited PDGF-BB-induced chemotaxis, and enhanced Rac1 
activity via an association with the c-Abl tyrosine kinase, while NRP-1 overexpression 
increased cell migration and TGF-beta-dependent collagen production [50]. The role of NRP1 
in PDGFRβ-mediated chemotaxis appears to result from enhanced receptor affinity for 125I-
PDGF-BB . Furthermore blockade of NRP1 using a neutralizing antibody reduced recruitment 
of HSCs, and decreased liver fibrosis in a rat model of liver injury, suggesting a role for NRP-1 
as a modulator of pathophysiological liver fibrosis [50]. 
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Other functions 
 
NRP1 expression has been reported in other cell types, including bone marrow-derived 
progenitor cells [202], platelets [203], and the granulosa and theca cells in the follicles of the 
bovine ovary [204], though the role of NRP1 in these systems has not yet been defined. A 
novel role for NRP1 has been identified in mediating cell entry of the Human T-cell 
lymphotropic virus type 1 (HTLV-1), apparently through viral mimicry of VEGF165 [205]. 
 
Conclusions and Perspectives 
 
 Neuropilins are receptors for Class III Semaphorins and for members of the VEGF 
family, with essential roles in neuronal patterning and cardiovascular development, 
respectively. Much evidence points to a key function of NRP1 in the migratory guidance of 
both axons and endothelial cells, a role that is presumably controlled by gradients of 
extracellular ligands and the co-expression of signalling receptors, plexins in neuronal cells and 
VEGFRs in endothelial cells. Though complex formation between NRPs and VEGFR2 or 
plexins seem to be key to understanding the mechanism of action of NRPs, in endothelial cells 
and neurons respectively, many other aspects of the molecular basis for NRP regulation of 
intracellular signalling or cell guidance remain enigmatic. Associations between the NRP 
carboxy-terminus and the PDZ domain protein, synectin, appears to offer a clue to the 
mechanism underlying the role of NRP1 in arteriolar morphogenesis, but does not explain the 
full complexity of NRP1 functions in development revealed by phenotypes of NRP1 deficient 
mice. Further work delineating the role of NRP protein-protein associations, and the 
identification of novel protein interactions with the NRP intracellular domain is likely to reveal 
novel insights into the mechanisms mediating NRP functions. 
 The different expression patterns and phenotypes of the respective mutant mice indicate 
that they play distinct roles in the development of both the neuronal and vascular systems, 
though they also have the ability to interact. While NRP2 is important for guidance of some 
classes of neuronal axons, the cellular function of NRP2 is less well studied than for NRP1, and 
it is unclear what its primary functions are in endothelial, lymphatic or cancer cells. In cells co-
expressing NRP1 and NRP2, how, if at all, do they interact and what is the impact on VEGFR2 
and plexin signalling? Does NRP2 play a modulatory or inhibitory role in NRP1 functions? 
Furthermore, while the most widely accepted model for NRP function is that NRPs are ligand-
binding but non-signalling co-receptors, unable to function independently of their partner 
receptors in neuronal and endothelial cells, evidence from studies in endothelial, cancer and T-
cells, does not readily fit this mechanistic paradigm, and suggests additional modes of NRP1 
function. NRP1 is expressed in cell types, such as immature T-cells and VSMC, which are not 
typical targets for either semaphorins or VEGFs, and many cancer cells may express NRP1 in 
the absence of co-expression of either VEGFRs or plexins. There is evidence that NRP1 may 
participate in homophilic adhesive interactions between cells, in, for example, the formation of 
early contacts – the so-called ‘immune synapse’ – between naïve T-lymphocytes and immature 
dendritic cells. The details of these cell-cell interactions, and the precise role NRP1 plays 
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remain to be elucidated, but they are suggestive that NRP1 plays roles independent of its 
known complement of ligands and receptor partners, particularly in adhesion.  
In addition to their major biological roles in neurogenesis and cardiovascular development, 
recent evidence has identified novel functions for NRPs in other physiological processes such 
as T-cell maturation, and in disease. A major recent development has been the emergence of a 
role for NRPs in cancer. NRPs are expressed on many tumour cells and they appear to be 
important in several aspects of tumour growth and spread, including cell migration and 
metastasis, interactions between neoplastic cells and the tumour microenvironment, T cell 
regulation of anti-tumour immunity and generation of cancer stem cells. Since the role of NRP1 
in cancer appears to be distinct from that of VEGF, targeting NRP1 may complement and 
potentiate the anti-tumour effects of therapies targeted at VEGF, such as bevacizumab. These 
findings indicate that therapeutic targeting of NRPs may offer a novel approach to the 
inhibition of tumour growth and metastasis. 
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Table 1. Phenotypes of Neuropilin and Synectin mutant mice. 
Key, NRP1Endo-/-, endothelial-specific NRP1 knockout; NRP1tg, mice globally overexpressing 
NRP1; NRP1Sema3A-/-, mice with a knock-in of a CUB domain deletion unable to bind Sema3A, 
NRP1Cyto, mice with a knock-in of NRP1 lacking the cytoplasmic domain. 
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Figure Legends 
 
Figure 1. Neuropilin gene organisation and protein structure. 
The NRP1 gene comprises 17 exons (black rectangles), encoding a full-length protein of 923 
amino acids (aa) consisting of an extracellular region with two tandem CUB (a1 and a2) 
domains (complement binding factors C1s/C1r, Uegf, Bone morphogenetic protein 1 BMP1), 
two tandem FV/VIII homology (b1 and b2) domains , a linker region and one MAM (c) domain 
(meprin, A5 antigen, receptor tyrosine phosphatase µ,); a single transmembrane domain (TM); 
and a 44 aa cytoplasmic (Cyt) domain  containing a C-terminal PDZ (post synaptic density 
protein (PSD95), Drosophila disc large tumor suppressor (DlgA), and zonula occuldens-1 
protein) binding domain motif, with the sequence, SerGluAla (SEA). Locations of binding sites 
for semaphorins and VEGF, and the putative oligomerisation domain are indicated. 
Arrowheads indicate: the positions of Ser 612 in NRP1, the major site of O-linked chondroitin 
sulphate glycosaminoglycan (CS-GAG) modification; insertion at residue 808 in NRP2 of five 
amino acids GlyGluAspPheLys (GENFK); and addition of 9 amino acids 
ValGlyCysSerTrpArgLeuProLeu (VGCSWRLPL) following truncation of the b2 domain at 
residue 548 in soluble NRP2 (sNRP2). Soluble NRP1 (sNRP1) is truncated at the linker region 
between the second FV/VIII and the MAM domain and ends with the 3 amino acids GlyIsoLys 
(GIK). Note that not all sNRP1 isoforms contain Ser 612, and are not all modifiable by CS-
GAG addition. Percentage amino acid homologies between the domains of full length NRP1 
and NRP2a isoforms (a1/a2, b1/b2, MAM, and intracellular domains, respectively, left to right) 
and between the NRP2a and NRP2b isoforms (extracellular region, and transmembrane domain 
plus intracellular domain, respectively) are indicated. 
 
Figure 2. Neuropilins, their ligands and co-receptors. 
A. Class 3 Semaphorins bind NRP1 and NRP2 with differing, and partially overlapping 
specificities and affinities. Plexins A1 and A2 are the major signalling receptors for class 3 
Semaphorins, and complex with NRPs and Semaphorins to form a holoreceptor essential for 
mediating effects of Semaphorins on growth cone collapse and axonal guidance in 
neurogenesis. The plexin cytoplasmic domain contains two blocks of homology shared with 
GTPase activating proteins. Key: IPT, immunoglobulin-like domains shared by plexins and 
transcription factors; MRS, Met-related sequences 
B. Specific isoforms of several members of the VEGF family bind with high affinity to NRP1 
and NRP2, with distinct specificities. VEGF specificities for their receptor tyrosine kinases are 
also shown. The major VEGF-A signalling receptor, VEGF receptor 2, (the human homologue 
called kinase insert domain-containing receptor, the mouse homologue, Flk-1; 
VEGFR2/KDR/Flk-1), forms complexes with NRP1 and is important for optimal VEGFR2 
signalling and function in endothelial cells. The VEGF-A121 isoform can bind to NRP1 but is 
unable to promote NRP1/VEGFR2 complexation. The role of NRP1 in VEGF-A signalling is 
likely to be important for mediating the essential functions of NRP1 in cardiovascular 
development revealed by mutant mouse studies. NRP1 has also been reported to associate with 
VEGFR1/Flt1, and NRP2 can complex with the receptor for VEGF-C and VEGF-D, VEGF 
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receptor 3, also called fms-related tyrosine kinase receptor 4 (VEGFR3/Flt-4). See text and 
legend to Fig.1 for key to abbreviations and further details. Key: Ig-like, immunoglobulin-like. 
 
Figure 3. VEGF signalling via NRP1 . 
A: VEGF (VEGF-A) is able to signal via VEGFR2 in the absence of NRP1. VEGF binding to 
VEGFR2 stimulates signalling via phospholipase C-gamma (PLC-γ), leading to activation of 
Protein kinase C (PKC) and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), 
and phosphoinositide 3-kinase (PI3K), mediating activation of the serine-threonine kinase, 
Akt/PKB (product of the oncogene encoded by the lymphomagenic murine retrovirus, AKT8, 
and activation of Focal adhesion kinase (FAK) via increased phosphorylation of Y397. 
B: VEGF-A165 binds to NRP1 and promotes complex formation. The NRP1 carboxy-terminal 
PDZ domain binding motif associates with the PDZ protein synectin and this is thought to be 
important for the role of NRP1 in VEGF-A signalling and function mediated via VEGFR2,. 
NRP1/VEGFR2 complex formation is implicated in signalling via p38 kinase, ERKs1/2, and a 
Pyk2 pathway leading to p130Cas tyrosine phosphorylation, via mechanism(s) that are still 
unclear. NRP1-dependent VEGF signalling is particularly important for directed cell migration. 
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